BETATINIB

Betatinib Capsule is a tyrosine kinase inhibitor, also known as a cancer growth inhibitor, primarily utilized for treating individuals with mantle cell lymphoma (MCL) who have undergone at least one previous treatment for their cancer. It is also prescribed for adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Cancer arises from genetic mutations that lead to uncontrolled cell division and the spread of these cells into surrounding tissues.

Betatinib Capsule contains Acalabrutinib, a specific tyrosine kinase inhibitor. Tyrosine kinases are enzymes that relay signals to cells, prompting them to grow and divide. Acalabrutinib works by blocking these signals in cancer cells, leading to cell death when their signaling is interrupted. This mechanism may help to slow down the advancement of cancer.

For effective treatment, it is essential to continue taking Betatinib Capsule for the duration prescribed by your doctor. Common side effects include anaemia (a deficiency of red blood cells), neutropenia (a reduced number of neutrophils), upper respiratory infections, thrombocytopenia (low platelet count), headaches, diarrhea, and musculoskeletal pain. If you experience any of these side effects persistently, consult your doctor.

It is advised not to use Betatinib Capsule if you are allergic to any of its components or if you have severe hepatic impairment. This medication can cause harm to a fetus if given to a pregnant woman. Therefore, it is crucial to avoid pregnancy during treatment and for several months afterward. Effective contraceptive methods are recommended while undergoing therapy with Betatinib Capsule. If you or your partner becomes pregnant during treatment, contact your doctor immediately. Breastfeeding is generally not recommended during this therapy, and alcohol consumption should be avoided while using this medication. The safety and efficacy of this drug in children have not been established.